Search PubMed⌕ Search

Biomedical subjects

J M Olivares

Publications and source records attributed to J M Olivares.

At least 19 recordsLinked to original sources

The anhedonias: a conceptual history.

BACKGROUND: The term and concept of 'anhedonia' refer to a group of clinical phenomena whose common denominator is the complaint of a putative incapacity to 'experience pleasure". Linked to disorders such as schizophrenia and depression, anhedonia remains difficult to define and measure. METHOD: This paper explores the historical frames in which anhedonia was originally constructed; and is fully based on primary sources. It makes use of the 'conceptual method', i.e. it differentiates the history of the word from that of the behaviours and concepts involved. RESULTS: Historical analysis shows that the boundaries of 'anhedonia' have been fuzzy since the time of Ribot, and that this has made it conceptually unstable. One reason for this instability pertains to the fact that from the start its definition has been parasitical upon the (itself evolving) concept of 'pleasure'. Another that it is defined negatively, i.e. as a reduction or abolition in a putative unitary function. Yet another, that there is little evidence that anhedonia itself is a unitary phenomenon. CONCLUSIONS: It is concluded that at this stage it might be advisable to refer to the concept in the plural (the anhedonias); that a definition should be formulated that it is less dependent upon the ongoing concept of pleasure; and that far more empirical research is needed to find out whether anhedonia is more than a final common pathway.

History, 19th Century↗

[Cognitive deficit and schizophrenia].

INTRODUCTION: In the present paper, the results of a number of different studies that have tried to establish the characteristics of the cognitive deficit in schizophrenia are discussed. The principal objective of this study was to ascertain whether exist statistically significative differences in such deficit in schizophrenic patients in relation with their preponderant symptomathology (positive symptoms, negative symptoms, and disorganization) or their degree of defectual symptoms. METHODOLOGY: Sixty three schizophrenic patients under treatment in a Day Hospital were divided in groups using the dimensions of Liddie and the Scale for assessing the Deficit Syndrome in Schizophrenia. Cognitive deficit was assessed by the Wisconsin Card Sorting Test (WCST). RESULTS: Our results show that education and gender has no relation with the cognitive deficit exhibited, whereas there is a direct relation with age and years suffering the illness. Patients who exhibited preponderant disorganization symptoms and those describes as defectual syndrome schizophrenics showed more cognitive deficit in the WCST. The number of preservations in the WCST seems to be the main deficit. CONCLUSIONS: The concept of planning in suggested as a schizophrenic marker in the frame of theories that claim there is a failure in the neurodevelopment of these patients.

Adult↗

[Incidence of extrapyramidal symptoms during treatment with olanzapine, haloperidol and risperidone: results of an observational study].

OBJECTIVES: To analyze the incidence of extrapyramidal symptoms (EPS) and the concomitant use of anticholinergic drugs in outpatients diagnosed of schizophrenia treated with olanzapine (OLZ) in comparison with haloperidol (HAL) and risperidone (RIS) under routine clinical practice conditions. MATERIAL AND METHODS: The analysis was carried out on the basis of the information obtained in the EFESO study, an observational, prospective study carried out in outpatients diagnosed of schizophrenia and treated with olanzapine compared to other antipsychotic agents used in the clinical practice. The incidence of EPS in the OLZ treated group compared to the haloperidol and risperidone treatment groups in which over 100 patients were included is analyzed in the present work. The study duration was 6 months and the data were collected by 293 psychiatrists from mental health care areas. RESULTS: The percentage of patients who presented at least one adverse event (AE) (p 3/4 0.001) was less in the OLZ groups (47.8%) compared to those of the HAL (79.8%) and RIS (57.2%) subgroups. A lower percentage of patients treated with OLZ (36.9%) presented EPS in comparison to the RIS (49.6%) and HAL (76%) subgroups (p 3/4 0.001). A lower rate of patients from the OLZ group (10.2%) received anticholinergic treatments compared to the RIS (19.9%) and HAL (44%) subgroups (p< 0.001 in both cases). CONCLUSIONS: OLZ-treated patients presented a lower incidence of EPS and required less anticholinergic treatment than the HAL and RIS treated patients. These results, obtained in naturalistic conditions, coincide with the conclusions reached in randomized clinical trials carried out prior to the marketing of OLZ.

Adult↗

[GEOPTE Scale of social cognition for psychosis].

INTRODUCTION: Despite the large number of scales to assess cognitive function, these are rarely used in clinical practice, both because of the time they require and because they do not give useful information to the clinician. The aim of this article is to present the characteristics and psychometric properties of a scale which aims, with its simplicity of use and design, to be of use in the clinical practice for measuring social cognition in psychosis. METHODS: The new GEOPTE Scale gathers information from two sources: the patient's subjective perception of his/her deficits and that of the informant or caregiver. It consists of 15 items (7 for basic cognitive functions and 8 for social cognition). The scale was applied to 87 patients with a diagnosis of psychosis (according to DSM-IV), and general clinical data, clinical global impression, mood and degree of insight were gathered. RESULTS: The GEOPTE Scale presented excellent internal consistency (Cronbach's alpha 0.84 for patient and 0.87 for informants). Factorial analysis identified two factors which explained a total variance of 39%. The first factor was related to the basic cognitive function items and the second to the social cognition items. Regarding the validity of the construct, the scores on the scale are closely related to clinical global impression, degree of insight and depressive symptoms. CONCLUSIONS: The GEOPTE Scale for measuring social cognition in psychosis has an excellent psychometric behavior both in the degree of internal consistency and in correlation with clinical global variables, mood and degree of insight.

Cognition Disorders↗

[Barcelona Bipolar Eating Disorder Scale (BEDS): a self-administered scale for eating disturbances in bipolar patients].

INTRODUCTION: The presence of eating disorders in bipolar population is not rare, with rates over 10 %, according to the few available epidemiologic studies, however the literature on this issue is still scarce. An even higher percentage of bipolar individuals suffer from serious problems related to eating behavior without fulfilling criteria for DSM-IV eating disorder. METHODS: The Bipolar Eating Disorders Scale (BEDS) was designed on the basis of the existing eating scales, adjusted to the characteristics of bipolar disorders from the complaints of our sample of patients (n=350). Subsequently, a group of experts made the selection of the most representative and independent items in order to obtain a short, 10-item scale, aimed at assessing the intensity and frequency of eating dysfunctions in the bipolar population and not at diagnosis. We administered the scale to a healthy control group (n=55) to evaluate feasibility and to determine the cut-off score. RESULTS: The BEDS is a 10-item simple, self-administered scale. Average time of completing this scale is about 1.13 min (1 min, 21 seconds) +/-26 seconds. Median score was 6 and the mean score was 6.6 with a standard deviation of 3.7, this being the reason why the cut-off point was found to be around 13 points. Patients receiving scores over 13 may require an individualized intervention to evaluate which were the main difficulties and to propose treatment. CONCLUSIONS: The BEDS allows for a rapid and effective evaluation of both the intensity and the frequency of eating dysfunctions in bipolar patients in order to perform an adequate intervention for the specific needs of each one of the patients.

Bipolar Disorder↗

[The European schizophrenia outpatient health outcomes (SOHO) study: baseline findings of the Spanish sample].

INTRODUCTION: To describe the baseline findings and study population of the Spanish sample of the Schizophrenia Outpatient Health Outcomes (SOHO) Study. METHOD: The SOHO study is an ongoing, large, prospective, long-term observational study of schizophrenia treatment in 10 European countries. The study population consists of outpatients who initiate therapy or change to a new antipsychotic. RESULTS: A total of 86 investigators enrolled 2,020 in Spain (10,972 patients in Europe). 64 % of patients were men and the mean age was 38.7 years. The Spanish SOHO study sample had considerable functional impairment at baseline. The main reason for change of therapy was lack effectiveness followed by intolerability. Patients included in the study and those receiving their first antipsychotic for schizophrenia are most likely to receive an atypical agent. CONCLUSION: The Spanish SOHO study population appears to represent the Spanish outpatients with schizophrenia in whom a treatment decision is required. Baseline findings reflect Spanish clinical practice with respect to patients treated with individual antipsychotics.

Adult↗

Validation of the Spanish version of the Social Functioning Scale.

INTRODUCTION: Social functioning as an outcome variable in therapeutic interventions with schizophrenic patients has been a relatively neglected area. The Social Functioning Scale (SFS) may be a good instrument to evaluate different therapeutical strategies for the rehabilitation of the schizophrenic patient. The aim of this paper is to validate the Spanish version of the SFS. MATERIAL AND METHODS: The Spanish version of the SFS was administered to 85 patients with schizophrenia (DSM-IV), and 120 healthy volunteers (60 unemployed and 60 employed). RESULTS: Cronbach's alpha is between 0.69 and 0.80 in every subscale. Item-total correlations show higher internal consistency than in the validation of the original English version of the SFS. Factorial analysis suggests it could be appropriate to use a mean score from every subscale to make a total score. Discriminant analysis differentiates between patients and controls in a statistically significant way. In order to facilitate the interpretation of the results and their clinical use, a conversion of the direct scores into standardized ones was carried out. CONCLUSIONS: Results from three samples show that the Spanish version of the Social Functioning Scale is reliable, valid, and sensitive.

Adult↗

[Quality of life and social functioning in schizophrenic patients treated with olanzapine: 1 year follow-up naturalistic study].

OBJECTIVE: To measure health related quality of life (HRQL) and social functioning in schizophrenic patients treated with olanzapine under regular clinical practice conditions. METHODS: Out-patients diagnosed of schizophrenia and beginning treatment with olanzapine, quetiapine, risperidone or typical oral antipsychotics were included. Information on socio-demographic characteristics was obtained and in each visit (baseline, 3, 6 and 12 months) they were administered the generic HRQL questionnaire Euro-QoL-5D (EQ-5D) and the Social Functioning Scale (SFS). RESULTS: A total of 1,198 patients were followed-up for 12 months. Mean age (SD) was 38.6 (13.3) years and 62.9 % of them were men. In basal conditions the most affected dimensions of EQ-5D were anxiety/depression (76 %), and daily activities (73.6 %). After 12 months treatment the cohort of patients treated with olanzapine showed a better HRQL in the self-care dimension compared to all other treatments (p < 0.05), and in the dimensions of pain/discomfort, anxiety/depression and usual activities compared to the group treated with quetiapine and risperidone (p < 0.05). The Visual Analogue Scale (VAS) of the EQ-5D questionnaire showed a better health state after 12 months in the group treated with olanzapine compared to the groups of quetiapine or risperidone (p < 0.05). The SFS showed a better improvement in the cohort of olanzapine in the three studied dimensions after 12 months: isolation and social relationships in comparison to the risperidone group (p < 0.05), interpersonal communication in comparison to the risperidone and quetiapine group (p < 0.05) and independence performance in comparison to all the other treatments (p < 0,05). CONCLUSION: Schizophrenic patients treated with olanzapine for one year show a better improvement in HRQL and social functioning than those treated with other antipsychotics.

Adult↗

[Analysis of prescription patterns of antipsychotic agents in psychiatry].

INTRODUCTION: We describe the different diseases in which conventional and second generation antipsychotic (APS) prescriptions are made. METHOD: Observational, retrospective, multicenter study based on the review of 300 clinical records of public and private sites, hospital and out-patient clinics, located in Salamanca, Vigo, Bilbao, Barcelona, Valencia, Oviedo and Malaga. RESULTS: The mean age of the population studied was 42 +/- 17 years; 56.6 % were men. Atypical drugs (67 %) were used basically versus classical ones (33 %). Classical APS are basically prescribed in bipolar disorder with/without psychotic symptoms (20.6 %), schizophrenia (18.3%) and delusional disorder (11.5 %). Atypical APS are fundamentally prescribed in schizophrenia (31.5 %), bipolar disorders with/without psychotic symptoms (12.5 %) and other psychotic disorders (8.9 %). When the psychotic disorders are considered by groups (schizophrenia, bipolar disorder with psychotic symptoms, delusional disorder and other psychotic disorders), classical APS are used in 47.4 % and atypical APS in 62.5%. APS were used ((outside the indication)) (off-label) in 32.8%, including resistant depressions, serious obsessive-compulsive disorder and borderline personality disorder, with similar percentages for both conventional and atypical ones. In dementia, atypical APS were used in 5.1 % versus 1.5 % of the conventional ones. The most frequent reasons for prescription of classical APS were control of psychotic symptoms (33.6 %), aggressiveness-agitation (31.3 %), severe insomnia (16 %), impulsivity (6.9 %) and severe anxiety (6.1 %). Atypical APS were preferably used in the control of psychotic symptoms (58.8%) and aggressiveness-agitation (25.5%). CONCLUSIONS: The use of APS basically occurs within their authorized indications (67.2 %). The off-label use (32.8 %) occurs both for the classical as well as atypical APS and occurs in serious diseases in which there are no alternative treatments.

Adult↗

[Treatment adherence in schizophrenia. A comparison between patient's, relative's and psychiatrist's opinions].

INTRODUCTION: Patients with psychiatric illness typically have great difficulty following a medication regimen, but they also have the greatest potential for benefiting from adherence. Due to the lack of insight in schizophrenia, adherence to treatment is especially important. We try to analyze and compare the opinion on adherence and compliance of psychiatrists, patients with schizophrenia and relatives. METHOD: A direct, anonymous survey specifically designed for the project was administered to psychiatrists, patients and relatives from all over Spain through different associations of patients and family legally constituted in Spain. Analysis was done separately for variables corresponding to the three groups. RESULTS: The psychiatrists (n = 844) considered that 56.8 % of their evaluated patients (n = 7.439) were noncompliers in the past month, as opposed to 43.2% of these patients who were considered good compliers (3,215 patients). Ninety-five percent of the patients (n = 938) stated that they took their medication regularly, while 5 % answered no to this question. Eighty-two percent of relatives (n = 796) think that patients regularly take their medication, but 47% state that they sometimes forget to take it. CONCLUSIONS: Treatment adherence should be evaluated in clinical trials and in research on treatment of diseases, particularly in chronic mental diseases such as schizophrenia. It seems clear that only programs aimed at detection and resolution of the problems involved in treatment adherence will be able to improve the mid- and long-term prognosis of patients with schizophrenic disorders.

Adolescent↗

[At risk for symptoms].

Explore the source record for details and available documents.

Borderline Personality Disorder↗

[A need to talk].

Explore the source record for details and available documents.

Confidentiality↗